Adoptive cell therapy using T cell receptors equipped with ICOS yields durable anti-tumor response

Abstract excerpt

Treatment with adoptively transferred T cells is challenged by limited longevity of therapeutic cells within tumors. To enhance the durability of anti-tumor T cell products, we have created T cell receptors (TCRs) with built-in co-stimulatory molecules. We observed that TCRs coupled to ICOS mediated exceptionally long-term responses including delay of tumor recurrence and cures in a mouse tumor model. TCR:ICOS T c...

Topics

Open a Topic to create a Post that cites this publication.

• Antigens, Neoplasm
• Autoantigens
• CAR-T cell therapy research
• Clinical Trials as Topic
• Immunotherapy, Adoptive
• Protein Engineering
• Receptors, Antigen, T-Cell
• T-Lymphocytes, Cytotoxic

Identifiers and source

Literature Corpus work

2e2bf9dc-a0ae-5853-934f-f259e0ed25b4

DOI

10.1101/2025.10.14.682056